{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:17:55Z","timestamp":1794331075737,"version":"4.9.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12325-018-0694-0","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T07:26:33Z","timestamp":1526628393000},"page":"939-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6698","authenticated-orcid":false,"given":"Lawrence","family":"Blonde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Dipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cadena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"694_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"key":"694_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/dom.12626","volume":"18","author":"K Khunti","year":"2016","unstructured":"Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR3","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2337\/dc13-0331","volume":"36","author":"K Khunti","year":"2013","unstructured":"Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411\u20137.","journal-title":"Diabetes Care"},{"key":"694_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3122\/jabfm.2009.05.080232","volume":"22","author":"RW Grant","year":"2009","unstructured":"Grant RW, Lutfey KE, Gerstenberger E, Link CL, Marceau LD, McKinlay JB. The decision to intensify therapy in patients with type 2 diabetes: results from an experiment using a clinical case vignette. J Am Board Fam Med. 2009;22:513\u201320.","journal-title":"J Am Board Fam Med"},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370:1514\u201323.","journal-title":"N Engl J Med"},{"key":"694_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","volume":"154","author":"WL Bennett","year":"2011","unstructured":"Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602\u201313.","journal-title":"Ann Intern Med"},{"key":"694_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-011-0094-1","volume":"29","author":"L Blonde","year":"2012","unstructured":"Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29:1\u201313.","journal-title":"Adv Ther"},{"key":"694_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"694_CR9","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl 1):S55\u201364.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"694_CR10","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc18-S008","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2018;41(Suppl 1):S73\u201385. https:\/\/doi.org\/10.2337\/dc18-S008","journal-title":"Diabetes Care"},{"key":"694_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018 executive summary. Endocr Pract. 2018;24:91\u2013120.","journal-title":"Endocr Pract"},{"key":"694_CR12","first-page":"1","volume":"2018","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142018 abridged for primary care providers. Clin Diabetes. 2018;2018:1\u201328.","journal-title":"Clin Diabetes"},{"key":"694_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.4158\/EP12436.OR","volume":"19","author":"SS Engel","year":"2013","unstructured":"Engel SS, Seck TL, Golm GT, Meehan AG, Kaufman KD, Goldstein BJ. Assessment of AACE\/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocr Pract. 2013;19:751\u20137.","journal-title":"Endocr Pract"},{"key":"694_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/dom.12399","volume":"17","author":"SA Ross","year":"2015","unstructured":"Ross SA, Caballero AE, Del Prato S, et al. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes Obes Metab. 2015;17:136\u201344.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/dom.12233","volume":"16","author":"OJ Phung","year":"2014","unstructured":"Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:410\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR16","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063\u20139.","journal-title":"Diabetes"},{"key":"694_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"key":"694_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","volume":"14","author":"T Haak","year":"2012","unstructured":"Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR19","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/ijcp.12308","volume":"67","author":"T Haak","year":"2013","unstructured":"Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 2013;67:1283\u201393.","journal-title":"Int J Clin Pract"},{"key":"694_CR20","doi-asserted-by":"publisher","first-page":"e0129477","DOI":"10.1371\/journal.pone.0129477","volume":"10","author":"EJ Ku","year":"2015","unstructured":"Ku EJ, Jung KY, Kim YJ, et al. Four-year durability of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes in clinical practice, COSMIC study. PLoS One. 2015;10:e0129477.","journal-title":"PLoS One"},{"key":"694_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","volume":"14","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505\u201324.","journal-title":"Expert Opin Drug Saf"},{"key":"694_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"694_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/dom.12093","volume":"15","author":"WB White","year":"2013","unstructured":"White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:668\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"694_CR25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579\u201388.","journal-title":"Circulation"},{"key":"694_CR26","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067\u201376.","journal-title":"Lancet"},{"key":"694_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","volume":"1","author":"DK McGuire","year":"2016","unstructured":"McGuire DK, Van de Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:126\u201335.","journal-title":"JAMA Cardiol"},{"key":"694_CR28","unstructured":"Takeda Pharmaceutical Company Limited. Prescribing information (12\/2016) NESINA\u00ae (alogliptin) tablets for oral use. http:\/\/general.takedapharm.com\/content\/file.aspx?FileTypeCode=NESINAPI&cacheRandomizer=bc4e3bc2-c132-4c86-bcc8-1263793d8d36. Accessed 10 April 2017."},{"key":"694_CR29","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (02\/2017) ONGLYZA\u00ae (saxagliptin) tablets, for oral use. http:\/\/www.azpicentral.com\/onglyza\/pi_onglyza.pdf. Accessed 12 April 2017."},{"key":"694_CR30","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin (updated 06\/07\/2016). 2016. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm486096.htm. Accessed 05 May 2017."},{"key":"694_CR31","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Prescribing information (08\/2017) TRADJENTA\u00ae (linagliptin) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/201280s016lbl.pdf. Accessed 14 Aug 2017."},{"key":"694_CR32","unstructured":"Merck & Co. Inc. Prescribing information (08\/2017) JANUVIA\u00ae (sitagliptin) Tablets. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf. Accessed 5 Sept 2017."},{"key":"694_CR33","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01243424?cond=Cardiovascular+Outcome+Study+of+Linagliptin&rank=1. Accessed 5 Sept 2017."},{"key":"694_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","volume":"12","author":"N Marx","year":"2015","unstructured":"Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA\u00ae). Diab Vasc Dis Res. 2015;12:164\u201374.","journal-title":"Diab Vasc Dis Res"},{"key":"694_CR35","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01897532?cond=Cardiovascular+Outcome+Study+of+Linagliptin&rank=2. Accessed 5 Sept 2017."},{"key":"694_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","volume":"43","author":"MB Rehman","year":"2017","unstructured":"Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43:48\u201358.","journal-title":"Diabetes Metab"},{"key":"694_CR37","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2337\/dc08-1755","volume":"32","author":"RA Noel","year":"2009","unstructured":"Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834\u20138.","journal-title":"Diabetes Care"},{"key":"694_CR38","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.2337\/dc13-2546","volume":"37","author":"I Raz","year":"2014","unstructured":"Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014;37:2435\u201341.","journal-title":"Diabetes Care"},{"key":"694_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2337\/dc15-1707","volume":"40","author":"I Tkac","year":"2017","unstructured":"Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40:284\u20136.","journal-title":"Diabetes Care"},{"key":"694_CR40","unstructured":"GlaxoSmithKline. Prescribing information (12\/2017) TANZEUM\u00ae (albiglutide) for injection, for subcutaneous use. https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/TANZEUM-PI-MG-IFU-COMBINED.PDF. Accessed 16 Jan 2018."},{"key":"694_CR41","unstructured":"Eli Lilly and Company. Prescribing information (08\/2017) TRULICITY\u2122 (dulaglutide) injection for subcutaneous use. http:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf. Accessed 24 Oct 2017."},{"key":"694_CR42","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (02\/2015) BYETTA (exenatide) injection. https:\/\/www.azpicentral.com\/byetta\/pi_byetta.pdf#page=1. Accessed 10 May 2017."},{"key":"694_CR43","unstructured":"Novo Nordisk Inc. Prescribing information (08\/2017) VICTOZA\u00ae (liraglutide) injection, for subcutaneous use. http:\/\/www.novo-pi.com\/victoza.pdf. Accessed 24 Oct 2017."},{"key":"694_CR44","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Prescribing information (12\/2017) JARDIANCE\u00ae (empagliflozin) tablets, for oral use. http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Jardiance\/jardiance.pdf. Accessed 15 Jan 2018."},{"key":"694_CR45","unstructured":"Janssen Pharmaceuticals, Inc. Prescribing Information (07\/2017) INVOKANA (canagliflozin) tablets, for oral use. https:\/\/www.invokana.com\/prescribing-information.pdf. Accessed 31 July 2017."},{"key":"694_CR46","unstructured":"Merck & Co., Inc. Prescribing information (12\/2017) STEGLATRO\u2122 (ertugliflozin) tablets, for oral use. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/steglatro\/steglatro_pi.pdf. Accessed 18 Jan 2018."},{"key":"694_CR47","unstructured":"Janssen Pharmaceuticals, Inc. Prescribing information (08\/2017) INVOKAMET\u00ae (canagliflozin and metformin hydrochloride) tablets, for oral use. https:\/\/www.invokamet.com\/sites\/www.invokamet.com\/files\/prescribing-information-invokamet.pdf?v=26. Accessed 15 Jan 2018."},{"key":"694_CR48","unstructured":"Janssen Pharmaceuticals Inc. Prescribing information (08\/2017) INVOKAMET\u00ae XR (canagliflozin and metformin hydrochloride extended release) tablets, for oral use. https:\/\/www.invokamet.com\/sites\/www.invokamet.com\/files\/prescribing-information-invokamet-xr.pdf?v=296. Accessed 16 Jan 2018."},{"key":"694_CR49","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (07\/2017) XIGDUO\u00ae XR (dapagliflozin and metformin HCL extended release) tablets, for oral use. http:\/\/www.azpicentral.com\/xigduo\/pi_xigduoxr.pdf. Accessed 15 Aug 2017."},{"key":"694_CR50","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Prescribing information (12\/2016) SYNJARDY\u00ae XR (empagliflozin and metformin hydrochloride extended-release) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208658s001lbl.pdf. Accessed 3 May 2017."},{"key":"694_CR51","unstructured":"Merck & Co., Inc. Prescribing information (12\/2017) SEGLUROMET\u2122 (ertugliflozin and metformin hydrochloride) tablets, for oral use. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/segluromet\/segluromet_pi.pdf. Accessed 18 Jan 2018."},{"key":"694_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1463-1326.2008.00993.x","volume":"11","author":"CJ Bailey","year":"2009","unstructured":"Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab. 2009;11:527\u201333.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR53","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2337\/dc16-0522","volume":"39","author":"S Hadjadj","year":"2016","unstructured":"Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016;39:1718\u201328.","journal-title":"Diabetes Care"},{"key":"694_CR54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","volume":"66","author":"RR Henry","year":"2012","unstructured":"Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446\u201356.","journal-title":"Int J Clin Pract"},{"key":"694_CR55","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520\u20139.","DOI":"10.1111\/dom.13103"},{"key":"694_CR56","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"694_CR57","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"694_CR58","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"694_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249\u201359.","journal-title":"Circulation"},{"key":"694_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2016.10.025","volume":"224","author":"RL Schilsky","year":"2017","unstructured":"Schilsky RL. Finding the evidence in real-world evidence: moving from data to information to knowledge. J Am Coll Surg. 2017;224:1\u20137.","journal-title":"J Am Coll Surg"},{"key":"694_CR61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/1573399812666160613113556","volume":"13","author":"MJ Levine","year":"2017","unstructured":"Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13:405\u201323.","journal-title":"Curr Diabetes Rev"},{"key":"694_CR62","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (10\/2017) FARXIGA\u00ae (dapagliflozin) tablets, for oral use. https:\/\/www.azpicentral.com\/farxiga\/pi_farxiga.pdf. Accessed 15 Jan 2018."},{"key":"694_CR63","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1517\/14740338.2015.1100167","volume":"14","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf. 2015;14:1879\u2013904.","journal-title":"Expert Opin Drug Saf"},{"key":"694_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","volume":"5","author":"S Kalra","year":"2014","unstructured":"Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5:355\u201366.","journal-title":"Diabetes Ther"},{"key":"694_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473\u20138.","journal-title":"J Diabetes Complications"},{"key":"694_CR66","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","volume":"70","author":"XP Yang","year":"2014","unstructured":"Yang XP, Lai D, Zhong XY, Shen HP, Huang YL. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70:1149\u201358.","journal-title":"Eur J Clin Pharmacol"},{"key":"694_CR67","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","volume":"38","author":"S Kohler","year":"2016","unstructured":"Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:1299\u2013313.","journal-title":"Clin Ther"},{"key":"694_CR68","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (updated 12\/04\/2015). 2015. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm. Accessed 1 June 2016."},{"key":"694_CR69","unstructured":"American Association of Clinical Endocrinologists, American College of Endocrinology. AACE\/ACE scientific and clinical review: association of SGLT2 inhibitors and DKA. 2015. https:\/\/aace.newshq.businesswire.com\/sites\/aace.newshq.businesswire.com\/files\/doc_library\/file\/SGLT2i_FINAL_DKA_Conclusions.pdf. Accessed 25 July 2016."},{"key":"694_CR70","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638\u201342.","journal-title":"Diabetes Care"},{"key":"694_CR71","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"N Erondu","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680\u20136.","journal-title":"Diabetes Care"},{"key":"694_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"694_CR73","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. 2017. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500965.htm. Accessed 24 May 2017."},{"key":"694_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","volume":"104","author":"FM Hasan","year":"2014","unstructured":"Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297\u2013322.","journal-title":"Diabetes Res Clin Pract"},{"key":"694_CR75","first-page":"719578","volume":"2014","author":"HW Lin","year":"2014","unstructured":"Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578.","journal-title":"Int J Endocrinol"},{"key":"694_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3810\/pgm.2011.01.2241","volume":"123","author":"S Jabbour","year":"2011","unstructured":"Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123:15\u201323.","journal-title":"Postgrad Med"},{"key":"694_CR77","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1758-5996-2-16","volume":"2","author":"J Levy","year":"2010","unstructured":"Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.","journal-title":"Diabetol Metab Syndr"},{"key":"694_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079904125003278","volume":"20","author":"L Blonde","year":"2004","unstructured":"Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20:565\u201372.","journal-title":"Curr Med Res Opin"},{"key":"694_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.diabres.2009.11.023","volume":"87","author":"MF Pollack","year":"2010","unstructured":"Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87:204\u201310.","journal-title":"Diabetes Res Clin Pract"},{"key":"694_CR80","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","volume":"27","author":"V Hutchins","year":"2011","unstructured":"Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157\u201368.","journal-title":"Curr Med Res Opin"},{"key":"694_CR81","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394\u2013402.","journal-title":"Diabetes Care"},{"key":"694_CR82","unstructured":"Centers for Disease Control and Prevention (CDC). About adult BMI. http:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/. Accessed 16 Aug 2017."},{"key":"694_CR83","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","volume":"54","author":"A Maida","year":"2011","unstructured":"Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia. 2011;54:339\u201349.","journal-title":"Diabetologia"},{"key":"694_CR84","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrendo.2016.86","volume":"12","author":"AA Tahrani","year":"2016","unstructured":"Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566\u201392.","journal-title":"Nat Rev Endocrinol"},{"key":"694_CR85","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2337\/dc12-1801","volume":"35","author":"MS Kirkman","year":"2012","unstructured":"Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650\u201364.","journal-title":"Diabetes Care"},{"key":"694_CR86","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","volume":"375","author":"RE Pratley","year":"2010","unstructured":"Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447\u201356.","journal-title":"Lancet"},{"key":"694_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431\u20139.","journal-title":"Lancet"},{"key":"694_CR88","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","volume":"14","author":"CF Deacon","year":"2012","unstructured":"Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes\u2013a review and meta analysis. Diabetes Obes Metab. 2012;14:762\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"694_CR89","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279\u201384.","journal-title":"Diabetes Care"},{"key":"694_CR90","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349\u201357.","journal-title":"Lancet"},{"key":"694_CR91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","volume":"143","author":"RJ Heine","year":"2005","unstructured":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559\u201369.","journal-title":"Ann Intern Med"},{"key":"694_CR92","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1463-1326.2009.01154.x","volume":"11","author":"MJ Davies","year":"2009","unstructured":"Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR93","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met\u2009+\u2009SU): a randomised controlled trial. Diabetologia. 2009;52:2046\u201355.","journal-title":"Diabetologia"},{"key":"694_CR94","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","volume":"375","author":"M Diamant","year":"2010","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234\u201343.","journal-title":"Lancet"},{"key":"694_CR95","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc12-1333","volume":"36","author":"M Davies","year":"2013","unstructured":"Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36:1368\u201376.","journal-title":"Diabetes Care"},{"key":"694_CR96","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/dom.12402","volume":"17","author":"JB Buse","year":"2015","unstructured":"Buse JB, Peters A, Russell-Jones D, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab. 2015;17:145\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR97","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ"},{"key":"694_CR98","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment. N Engl J Med. 2014;370:794\u20137.","journal-title":"N Engl J Med"},{"key":"694_CR99","doi-asserted-by":"publisher","first-page":"i581","DOI":"10.1136\/bmj.i581","volume":"352","author":"L Azoulay","year":"2016","unstructured":"Azoulay L, Filion KB, Platt RW, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016;352:i581.","journal-title":"BMJ"},{"key":"694_CR100","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11:202\u201330.","journal-title":"Rev Diabet Stud"},{"key":"694_CR101","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"694_CR102","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"694_CR103","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"694_CR104","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (10\/2017) BYDUREON\u00ae (exenatide extended-release) for injectable suspension. http:\/\/www.azpicentral.com\/bydureon\/pi_bydureon.pdf. Accessed 24 Oct 2017."},{"key":"694_CR105","unstructured":"Novo Nordisk Inc. Prescribing information (12\/2017) OZEMPIC\u00ae (semaglutide) injection, for subcutaneous use. http:\/\/www.novo-pi.com\/ozempic.pdf. Accessed 17 Jan 2018."},{"key":"694_CR106","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384\u201393.","journal-title":"Diabetes Care"},{"key":"694_CR107","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information (02\/2017) QTERN\u00ae (dapagliflozin and saxagliptin) tablets, for oral use. http:\/\/www.azpicentral.com\/qtern\/qtern.pdf. Accessed 10 May 2017."},{"key":"694_CR108","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376\u201383.","journal-title":"Diabetes Care"},{"key":"694_CR109","doi-asserted-by":"publisher","unstructured":"Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2017. https:\/\/doi.org\/10.1111\/dom.13194.","DOI":"10.1111\/dom.13194"},{"key":"694_CR110","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015;17:268\u201375.","journal-title":"Diabetes Obes Metab"},{"key":"694_CR111","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jdiacomp.2014.06.004","volume":"28","author":"SN Rajpathak","year":"2014","unstructured":"Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications. 2014;28:831\u20135.","journal-title":"J Diabetes Complications"}],"updated-by":[{"DOI":"10.1007\/s12325-018-0729-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0694-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0694-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0694-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:27:15Z","timestamp":1724412435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0694-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0694-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-018-0729-6","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \u201cCombination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations\u201d.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}